Current Report Filing (8-k)
February 19 2014 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 18, 2014
Chelsea TherapEUtics International, Ltd. |
(Exact name of registrant as specified in its charter) |
Delaware |
000-51462 |
20-3174202 |
(State or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer ID Number) |
3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277 |
(Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code: (704)
341-1516
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
On February 18, 2014,
Chelsea Therapeutics International, Ltd. issued a press release announcing that the U.S. Food and Drug Administration had granted
accelerated approval of Northera™ (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension. A copy
of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit
No. | |
Description |
|
| |
|
|
99.1 | |
Press release dated February
18, 2014. |
Signature
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. |
|
|
|
|
By: |
/s/ J. Nick Riehle |
|
|
J. Nick Riehle |
|
|
Chief Financial Officer |
|
|
|
Dated: February 18, 2014 |
|
|
Exhibit Index
Exhibit No. | |
Description |
| |
|
99.1 | |
Press release dated February 18, 2014. |
Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chelsea Therapeutics International, Ltd. (MM) (NASDAQ:CHTP)
Historical Stock Chart
From Jul 2023 to Jul 2024